TP53 and cancer: Across 12 major cancer types (excluding HCC), 42% of cancers harbored TP53 somatic mutations, with at least 20% mutational rate in 10/12 cancer types and TP53 mutations are associated with inferior prognosis and unfavorable clinicopathologic parameters, such as tumor stage (Kandoth et al., 2013).